- Home
- Companies
- canada saskatchewan
- antigen present
Show results for
Refine by
Antigen Present Suppliers Serving Saskatchewan
33 companies found
based inHolytown, UNITED KINGDOM
We are developing safer, less expensive CAR-T products which can target more cancers and save more lives. We do this using our integrated model which drives the development of our products through preclinical testing to the clinic. Our mission is to ...
Our therapies are focused on leveraging the inherent biological capabilities of gamma delta T cells (GDT cells) together with an integrated cell engineering approach. GDT cells are a component of the lymphocytes (white blood cells) present within ...
based inOxford, UNITED KINGDOM
ProImmune’s mission is to be your partner of choice for understanding and managing adaptive immune responses. We offer unique solutions for preclinical and clinical immunology research, including a comprehensive and integrated antigen ...
CD1d Tetramers the world’s leading product for tracking NKT cells. Detect NKT Cells with CD1d Tetramers: ProImmune is the leading commercial source worldwide for fluorescently labeled human and mouse CD1d tetramers. CD1d-lipid complexes bind ...
based in, MASSACHUSETTS (USA)
MtoZ Biolabs is an integrate contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. The ...
Nanoparticles (NPs) undergo interactions with serum proteins during systemic administration, which may result in the formation of protein corona (PC). Investigating the interplay between the chemical and biological properties of NPs enhances ...
based inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
Immunotherapeutic cancer vaccines have generated a lot of interest from oncologists since it was discovered that immune activation can lead to a specific antitumor response.1 However, despite initial progress, most cancer vaccines have failed to ...
based inWürzburg, GERMANY
Toleris Biotherapeutics GmbH is a biotechnology company based in Würzburg, Germany. The company specializes in the development of innovative biotherapeutic solutions aiming to advance the field of medicine through cutting-edge scientific research. ...
AIM Bio has developed a platform of Autoimmunity Modifying Biologicals (AIM Biologicals) that uses soluble, near-physiological proteins to induce selective, antigen-specific immune tolerance. These proteins mimic a natural process ...
based inNew Taipei City, TAIWAN
For EirGenix Inc., health is important for all people. Under this belief, EirGenix established two business units to achieve the goal. One is contract development and manufacturing operation unit where EirGenix helps clients to manufacture their ...
CRM197 has been tested in animals studies and it has been demonstrated to lack toxicity. CRM197 can be used as a carrier protein for vaccine delivery. It acts by helping polysaccharide antigens to bind on and be internalized into ...
based inGosselies, BELGIUM
SYnAbs was founded in 2015 as a Belgian spin-off of the Catholic University of Louvain (UCL), based on the work of Prof. Hervé Bazin, the inventor of the world's first rat myeloma cell line. SYnAbs' vision is to fill the gap on the marketplace for ...
Transmembrane proteins are probably the most complex and challenging antigens to target with monoclonal antibodies. Indeed, despite their strong presence in the animal kingdom and their implications in many cellular mechanisms, they remain very ...
based inDuluth, GEORGIA (US) (USA)
The products that make up the BIVI portfolio help animals feel better, perform better and live better. A guiding principle of the Boehringer family has always been to provide Value through Innovation to our customers. We strive to provide our ...
Vetera Gold XP is a combination vaccine for horses, protecting against multiple diseases in a single 1 mL dose. It is effective for healthy horses aged 4 months or older, including pregnant mares. The vaccine protects against Eastern and Western ...
based inHolliston, MASSACHUSETTS (USA)
BTX has been at the forefront of electroporation technology since we introduced the first commercially available electroporator in 1983. For over 30 years, we have made it our priority to focus only on electroporation and electrofusion. This focus ...
The AgilePulse In Vivo System, used for animal immunization, vaccine development, and gene therapy, provides an intra-muscular, intra-dermal, or intra-tumor electroporation solution to produce maximum transfection efficiency. Traditional in vivo ...
based inOslo, NORWAY
NEC OncoImmunity AS is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning based software, which addresses the key knowledge gaps in the prediction of bona fide immunogenic antigens for personalized cancer ...
Recent advances in the field of immuno-oncology have established that mutated antigens (neoantigens), are viable targets of the immune system, potentially specific to each individual cancer patient. This plus many other breakthroughs in ...
based inNew Orleans, LOUISIANA (USA)
Our mission is to advance infectious disease diagnosis and improve patient care using novel diagnostic platforms that produces rapid and accurate results from patient samples. Our versatile platforms address critical needs for current infectious ...
based inLoveland, COLORADO (USA)
Through innovation, invention, and strategic partnerships with worldwide leaders in diagnostics and treatments, Heska provides the benefits of latest generation technologies to pet healthcare providers. Heska’s range of complete blood diagnostic ...
The safest long term allergy treatment solution for canine, feline or equine ...
based inMinneapolis, MINNESOTA (USA)
Bio-Techne empowers researchers in Life Science and Clinical Diagnostics by providing high-quality reagents, instruments, custom manufacturing, and testing services. Our family of brands creates a unique portfolio of products and services. Science ...
Immune cell therapy is rapidly emerging as an important alternative for cancer treatment, as well as treatment of autoimmune disease. Also known as adoptive cell therapy or cellular immunotherapy, it supercharges an individual’s immune ...
based inCarlsbad, CALIFORNIA (USA)
Founded in 1996, IVD Research, Inc. is privately held by Dave Lambillotte, Ann Marie Martin and Christopher Lambillotte. Our tight-knit group of dedicated professionals works well as a team, each bringing their own unique experiences and education ...
Giardiasis, caused by the single-celled Giardia lambliaparasite, is the most common parasitic disease in the United States. As many as 100 million mild infections and 1 million severe infections are reported ...
based inSan Mateo de Gállego Zaragoza, SPAIN
CerTest Biotec, S.L. is an independent biotechnology company devoted to the development and manufacturing of IVD diagnostic products in human clinical field. An innovative technology-based company whose success lies in its human capital, highly ...
CerTest Legionella one step card test is a coloured chromatographic immunoassay for the qualitative detection of Legionella pneumophila serogroup 1 in human urine samples. CerTest Legionella card test offers a highly sensitive and simple screening ...
based inCambridge, MASSACHUSETTS (USA)
VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP ...
When properly stimulated, the human immune system is incredibly powerful and has profound potential. Because of their structural similarity to viruses presented in nature, including their particulate nature and repetitive structure, ...
based inSeoul, SOUTH KOREA
GI Innovation is a bio-venture company that researches and develops innovative protein new drugs through well-structured translational research. The primary research and development for GI Innovation is immuno-oncology drug and allergy disease and ...
Promotes the generation of cancer-specific effector T cell (Teff) in lymph nodes, and induces the activation and proliferation of tumor-infiltrating Teff and NK cells. Controls the immuno-suppressive function of regulatory T cells (Tregs) in tumor ...
based inOxford, UNITED KINGDOM
The Native Antigen Company has developed a proprietary HEK293 mammalian expression system (VirtuE) for expression of recombinant proteins. The Native Antigen Company has rapidly become one of the world’s leading suppliers of infectious disease ...
Recombinant Chikungunya Virus-Like Particles produced in mammalian HEK293 cells. Chikungunya structural proteins are transiently expressed to form a particle comprising E1, E2 and capsid protein, without the non-structural proteins or genome. ...
based inBelfast, UNITED KINGDOM
Biopanda Reagents develops and manufactures in vitro test kits for clinical laboratories, veterinary practice, environmental protection, and food safety, both locally and globally. Our company provides innovative, high quality and cost-effective ...
The Biopanda TB-ELiFN kit is an enzyme linked immunosorbent assay (ELISA) for the quantitative determination of Interferon gamma (IFN-γ) released by memory T cells in human whole blood through in vitro stimulation with specific Mycobaterium ...
based inWest Vancouver, BRITISH COLUMBIA (CANADA)
Focusing initially on breast cancer, BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) is dedicated to enhancing the lives of people with cancer with limited therapy options by developing novel immunotherapies to fight cancer. ...
We believe that Bria-IMT™/Bria-OTS™, activates the patient’s immune system to recognize tumor cells and destroy them. We hypothesize that Bria-IMT™/Bria-OTS™, exert their action by stimulating the ...
